多因素联合对于肺癌骨转移的诊断价值

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (685 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the diagnostic value of multi-factorial combination in bone metastasis of lung cancer. Methods From January 2013 to December 2015, 126 newly diagnosed lung cancer patients from Department of Chemoradiotherapy in Tangshan People′s Hospital were selected in this study. The serum levels of NTx and ALP were measured and the information of clinical characteristics such as sex, age and the Karnofsky's index of performance status (KPS) score were collected. The bone metastasis was diagnosed by ECT combined with CT and MRI. Patients were grouped according to the presence or absence of bone metastasis. ROC curves were used to examine the diagnostic value of NTx, ALP and KPS and determine the best cutoff value. The correlation between bone metastasis and aforementioned factors was analyzed by logistic regression analysis. The multi-factorial combination which was produced though Logistic regression analysis was valued by ROC test again. Results The rate of bone metastasis was 34.1%. After being grouped, ROC analysis indicated that the optimal cutoff value of NTx, ALP and KPS were 21.5 nmol/L, 94 U/L and 80. The areas under the ROC curve of NTx, ALP and KPS were 0.792, 0.641 and 0.644. The sensitivities were 65.1%, 46.5% and 74.4% and the specificities were 84.3%, 81.9% and 44.6% respectively. Univariate and multivariate analysis showed NTx, ALP and KPS were significantly correlated with bone metastasis（P < 0.05）. Further ROC test demonstrated that the multi-factorial combination got a better diagnostic result (area under the ROC curve 0.861, sensitivity 74.4% and specificities 86.7%). Conclusion Serum NTx, Serum ALP and KPS were independent factors corrected with bone metastasis. Multi-factorial combination has a higher diagnostic result than single factor. Further multi-center studies with large sample should be conducted to confirm the result.

Key words： Lung cancer Bone metastasis Biomarkers Collagen Type Ⅰ collagen pyridinoline cross-linked N-telo peptides

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Qiong MA Haiying ZHANG Mingming WANG Zhiwu▲ WANG Xuechen CUI Zejun

Cite this article:

WU Qiong MA Haiying ZHANG Mingming WANG Zhiwu▲ WANG Xuechen CUI Zejun. Diagnostic value of multi-factorial combination for bone metastasis of lung cancer[J]. 中国医药导报, 2018, 15(16): 55-58.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I16/55

[1] Santini D，Barni S，Intagliata S，et al. Natural history of non-small-cell lung cancer with bone metastases [J]. Sci Rep，2015，5：18 670.
[2] Kong P，Yan J，Liu D，et al. Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - a retrospective analysis [J]. Medicine（Baltimore），2017，96（51）：e9327.
[3] Wang H，Zhang Y，Zhu H，et al. Risk factors for bone metastasis in completely resected non-small-cell lung cancer [J]. Future Oncol，2017，13（8）：695-704.
[4] Espinosa JC，Herrero FR，Martin EH，et al. Seom guidelines for the treatment of bone metastases from solid tumours [J]. Clin Transl Oncol，2012，14（7）：505-511.
[5] 魏强，程洁，田丛娜，等.磁共振全身弥散成像联合核素全身骨显像在骨转移瘤诊断中应用价值[J].中国医药导报，2016，13（10）：19-22.
[6] O'Sullivan GJ，Carty FL，Cronin CG. Imaging of bone metastasis：an update [J]. World J Radiol，2015，7（8）：202-211.
[7] D'Oronzo S，Brown J，Coleman R. The value of biomarkers in bone metastasis [J]. Eur J Cancer Care（Engl），2017. DOI：10.1111/ecc.12725.
[8] Liu B，Zhao Y，Yuan J，et al. Elevated n-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer：a meta-analysis [J]. PLoS One，2017，12（11）：e0187860.
[9] Zhou Y，Yu QF，Peng AF，et al. The risk factors of bone metastases in patients with lung cancer [J]. Sci Rep，2017，7（1）：8970.
[10] Sun Y，Ai X，Shen S，et al. Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases [J]. Patient Prefer Adherence，2015，9：1165-1169.
[11] Esposito M，Guise T，Kang Y. The biology of bone metastasis [J]. Cold Spring Harb Perspect Med 2017. DOI：10.1101/cshperspect.a031252.
[12] Luo Q，Xu Z，Wang L，et al. Progress in the research on the mechanism of bone metastasis in lung cancer [J]. Mol Clin Oncol，2016，5（2）：227-235.
[13] Tamiya M，Suzuki H，Kobayashi M，et al. Usefulness of the serum cross-linked n-telopeptide of type Ⅰ collagen as a marker of bone metastasis from lung cancer [J]. Med Oncol，2012，29（1）：215-218.
[14] 孙辉，陈晓霞，赵印敏，等. Ntx检测在肺癌骨转移中的诊断和判断疗效价值[J].中华胸心血管外科杂志，2013， 29（3）：172-173.
[15] Tamiya M，Tokunaga S，Okada H，et al. Evaluation of bone metastasis using serial measurements of serum n-telopeptides of type Ⅰ collagen in patients with lung cancer：a prospective study [J]. Anticancer Res，2015，35（7）：3987-3993.
[16] Huang J，Gu T，Ying J. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer [J]. Int J Clin Oncol，2017，22（6）：1015-1025.
[17] 刘志武，李莉，谭榜云，等.血清ODF和OCIF及Ca ALP水平在肺癌骨转移中临床研究[J].西部医学，2014， 26（2）：239-241.
[18] 阿米娜，曲海，韩记真，等.多学科团队模式护理干预对老年晚期肺癌伴骨转移患者治疗依从性，癌因性疲乏及焦虑抑郁的影响[J].中国医药导报，2017，14（25）：167-170.
[19] Charpidou A，Tsagouli S，Gkiozos I，et al. Bone metastases in patients with small cell lung carcinoma：rate of development，early versus late onset，modality of treatment，and their impact on survival. A single-institution retrospective cohort study [J]. Clin Exp Metastasis，2016， 33（5）：453-460.
[20] Aiba H，Kimura T，Yamagami T，et al. Prediction of skeletal-related events in patients with non-small cell lung cancer [J]. Support Care Cancer，2016，24（8）：3361-3367.